Connecticut Wealth Management LLC grew its stake in shares of Stryker Co. (NYSE:SYK - Free Report) by 92.2% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,401 shares of the medical technology company's stock after buying an additional 672 shares during the quarter. Connecticut Wealth Management LLC's holdings in Stryker were worth $504,000 as of its most recent SEC filing.
Other large investors also recently modified their holdings of the company. Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Stryker during the fourth quarter valued at about $25,000. Rakuten Securities Inc. increased its position in Stryker by 618.2% in the 4th quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company's stock valued at $28,000 after acquiring an additional 68 shares during the period. Centricity Wealth Management LLC bought a new position in shares of Stryker during the fourth quarter valued at $30,000. BankPlus Trust Department acquired a new position in shares of Stryker during the fourth quarter worth $33,000. Finally, Activest Wealth Management acquired a new stake in Stryker in the fourth quarter valued at $36,000. 77.09% of the stock is currently owned by institutional investors.
Insiders Place Their Bets
In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the stock in a transaction on Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total value of $75,392,000.00. Following the sale, the director now directly owns 3,417,326 shares in the company, valued at approximately $1,288,195,208.96. This trade represents a 5.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 5.90% of the company's stock.
Stryker Stock Performance
NYSE SYK traded up $7.18 during trading hours on Tuesday, reaching $383.80. The company's stock had a trading volume of 745,536 shares, compared to its average volume of 1,347,413. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. Stryker Co. has a 52 week low of $314.93 and a 52 week high of $406.19. The business has a 50-day simple moving average of $368.04 and a 200 day simple moving average of $376.15. The stock has a market cap of $146.49 billion, a PE ratio of 49.46, a PEG ratio of 2.93 and a beta of 0.93.
Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, topping analysts' consensus estimates of $2.73 by $0.11. The firm had revenue of $5.87 billion during the quarter, compared to analyst estimates of $5.68 billion. Stryker had a net margin of 13.25% and a return on equity of 23.58%. The company's revenue was up 11.9% on a year-over-year basis. During the same quarter last year, the business posted $2.50 EPS. Equities research analysts predict that Stryker Co. will post 13.47 earnings per share for the current fiscal year.
Stryker Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Thursday, July 31st. Stockholders of record on Monday, June 30th will be paid a $0.84 dividend. The ex-dividend date is Monday, June 30th. This represents a $3.36 annualized dividend and a dividend yield of 0.88%. Stryker's dividend payout ratio is presently 45.41%.
Analyst Upgrades and Downgrades
SYK has been the topic of a number of recent analyst reports. Wall Street Zen downgraded shares of Stryker from a "buy" rating to a "hold" rating in a research report on Thursday, March 6th. Argus set a $450.00 price objective on Stryker in a research note on Monday, February 3rd. BTIG Research set a $403.00 price objective on shares of Stryker and gave the company a "buy" rating in a research note on Monday, April 14th. JMP Securities reaffirmed a "market perform" rating on shares of Stryker in a research note on Monday, May 5th. Finally, Barclays lifted their price target on Stryker from $418.00 to $443.00 and gave the company an "overweight" rating in a research report on Monday, February 10th. Five analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $427.30.
Check Out Our Latest Analysis on Stryker
Stryker Company Profile
(
Free Report)
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.
Further Reading
Before you consider Stryker, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stryker wasn't on the list.
While Stryker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
